Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2 2Phase 1/2 2

Status

Recruiting 2Suspended 1Active not recruiting 1

Sponsor Class

NIH 4

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 2Gynecologic 1Breast 1

Conditions

Leukemia, Myeloid, Acute 6Multiple Myeloma 5Prostatic Neoplasms 4Neoplasm Metastasis 4Myelodysplastic Syndromes 4Lung Neoplasms 4Breast Neoplasms 4Carcinoma, Non-Small-Cell Lung 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Mycosis Fungoides 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, B-Cell 2Leukemia, Biphenotypic, Acute 2Glioma 2Colorectal Neoplasms 2Osteosarcoma 1Opioid-Related Disorders 1Neurofibrosarcoma 1Neurofibromatosis 1 1Neuroblastoma 1Neoplasms 1Melanoma 1Medulloblastoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1

Interventions

pembrolizumab 58Gemcitabine 37Biopsy 33Specimen Handling 32Paclitaxel 30Magnetic Resonance Spectroscopy 30Nivolumab 29Cisplatin 25Irinotecan 24Carboplatin 24Cyclophosphamide 23Fluorouracil 22Bevacizumab 22Docetaxel 21Oxaliplatin 19Leucovorin 18Ipilimumab 17Cetuximab 17Capecitabine 17130-nm albumin-bound paclitaxel 16Everolimus 15Albumin-Bound Paclitaxel 15Trastuzumab 13olaparib 12Pemetrexed 12Erlotinib Hydrochloride 12spartalizumab 11Sorafenib 11Radiosurgery 11trastuzumab deruxtecan 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × Neoplasm Metastasis × X-Rays × Clear all
NCT04840589 2026-05-13

Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors

National Cancer Institute (NCI)

Phase 1 Suspended
66 enrolled
Gynecologic

Neoplasm Metastasis, Ovarian Neoplasms

NCT05372640 2026-05-13

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

National Cancer Institute (NCI)

Phase 1 Recruiting
45 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT05687110 2026-05-13

Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes

National Cancer Institute (NCI)

Phase 1 Recruiting
43 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT03842228 2026-04-29

COD

National Cancer Institute (NCI)

Phase 1 Active not recruiting
39 enrolled 15 charts
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡